Alexander Bernhardt
Impact in
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
- Drug Solubulity and Delivery Systems
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Parkinson's Disease Mechanisms and Treatments 5
- Neurological disorders and treatments 4
-
- Drug Solubulity and Delivery Systems 4
- Advanced Drug Delivery Systems 4
- Co-authors
- Andrea Engel (4 shared papers)Carl G. Figdor (3 shared papers)Silko Grimm (3 shared papers)Oya Tagit (3 shared papers)Sandra Klein (4 shared papers)Martin Hrubý (2 shared papers)Eliézer Jäger (2 shared papers)Simone Baiardi (2 shared papers)
- Journals
- Movement Disorders (3 papers)AAPS PharmSciTech (2 papers)Pharmaceutics (2 papers)Acta Neuropathologica Communications (1 paper)Investigational New Drugs (1 paper)
- Partner nations
- GermanyUnited StatesNetherlands
In The Last Decade
Alexander Bernhardt
15 papers receiving 326 citations
Alexander Bernhardt's Hit Papers
Peers
Comparison fields: 5 of 87
- Pharmaceutical Science 110
- Biomaterials 111
- Neurology 37
- Molecular Medicine 12
- Biomedical Engineering 98
Countries citing papers authored by Alexander Bernhardt
This map shows the geographic impact of Alexander Bernhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Bernhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Bernhardt more than expected).
Fields of papers citing papers by Alexander Bernhardt
This network shows the impact of papers produced by Alexander Bernhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Bernhardt. The network helps show where Alexander Bernhardt may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexander Bernhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 180 | |
| 2 | 2022 | 28 | |
| 3 | 2022 | 22 | |
| 4 | 2024 | 20 | |
| 5 | 2021 | 17 | |
| 6 | 2022 | 17 | |
| 7 | A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease Hit paper breakdown → | 2025 | 13 |
| 8 | 2022 | 7 | |
| 9 | 2024 | 5 | |
| 10 | 2021 | 4 | |
| 11 | 2019 | 4 | |
| 12 | 2022 | 4 | |
| 13 | 2013 | 3 | |
| 14 | 2024 | 1 | |
| 15 | 2025 | 1 | |
| 16 | 2025 | 0 | |
| 17 | 2025 | 0 |
About Alexander Bernhardt
Alexander Bernhardt is a scholar working on Neurology, Pharmaceutical Science, Pulmonary and Respiratory Medicine, Cognitive Neuroscience and Cardiology and Cardiovascular Medicine, having authored 17 papers that have together received 326 indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (5 papers), Drug Solubulity and Delivery Systems (4 papers), Neurological disorders and treatments (4 papers), Advanced Drug Delivery Systems (4 papers), Analytical Methods in Pharmaceuticals (2 papers), Crystallization and Solubility Studies (2 papers), Functional Brain Connectivity Studies (2 papers) and Advanced Neuroimaging Techniques and Applications (1 paper). The work is most often cited by research in Pharmaceutical Science (110 citations), Biomaterials (111 citations), Neurology (37 citations), Molecular Medicine (12 citations) and Biomedical Engineering (98 citations). Alexander Bernhardt has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Andrea Engel, Carl G. Figdor, Silko Grimm, Oya Tagit, Sandra Klein, Martin Hrubý, Eliézer Jäger, Simone Baiardi, Marcello Rossi and Piero Parchi. Their work appears in journals such as Movement Disorders, AAPS PharmSciTech, Pharmaceutics, Acta Neuropathologica Communications and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.